Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45–56 (2019).

Article  CAS  PubMed  Google Scholar 

Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396, 839–852 (2020).

Article  PubMed  Google Scholar 

Locke, F. L. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N. Engl. J. Med. 386, 640–654 (2022).

Article  CAS  PubMed  Google Scholar 

Kamdar, M. et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 399, 2294–2308 (2022).

Article  CAS  PubMed  Google Scholar 

Bishop, M. R. et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N. Engl. J. Med. 386, 629–639 (2022).

Article  CAS  PubMed  Google Scholar 

Sehgal, A. et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet. Oncol. 23, 1066–1077 (2022).

Article  CAS  PubMed  Google Scholar 

Neelapu, S. S. et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat. Med. 28, 735–742 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jaglowski, S. et al. Tisagenlecleucel chimeric antigen receptor (CAR) T-cell therapy for adults with diffuse large B-cell lymphoma (DLBCL): real world experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry [abstract]. Blood 134 (Suppl. 1), 766 (2019).

Article  Google Scholar 

Crombie, J. L. et al. Multicenter, real-world study in patients with R/R large B-cell lymphoma (LBCL) who received lisocabtagene maraleucel (liso-cel) in the United States (US) [abstract]. Blood 142 (Suppl. 1), 104 (2023).

Article  Google Scholar 

Pasquini, M. C. et al. Post-marketing use outcomes of an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, axicabtagene ciloleucel (Axi-Cel), for the treatment of large B cell lymphoma (LBCL) in the United States (US) [abstract]. Blood 134 (Suppl. 1), 764 (2019).

Article  Google Scholar 

Perera, N. et al. Real-world outcomes with CD19 CAR T-cell therapy for B-cell malignancies in regional/rural australia: results from the Queensland CAR T-cell program [abstract]. Blood 140 (Suppl. 1), 7500–7501 (2022).

Article  Google Scholar 

Alasbali, R. et al. The outcome of tisagenlecleucel (Tisa-Cel) vs axicabtagene ciloleucel (Axi-Cel) CD-19 CAR-T cell therapy in relapsed/refractory NHL, real world data, single institution experience [abstract]. Blood 142 (Suppl. 1), 6936 (2023).

Article  Google Scholar 

Goto, H. et al. Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma. Int. J. Clin. Oncol. 25, 1736–1743 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jacobson, C. A. et al. Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity. J. Clin. Oncol. 38, 3095–3106 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nastoupil, L. J. et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T consortium. J. Clin. Oncol. 38, 3119–3128 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Riedell, P. A. et al. A multicenter retrospective analysis of clinical outcomes, toxicities, and patterns of use in institutions utilizing commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B-cell lymphomas [abstract]. Blood 134 (Suppl. 1), 1599 (2019).

Article  Google Scholar 

Iacoboni, G. et al. Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma. Cancer Med. 10, 3214–3223 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Othman, T. et al. Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma. Br. J. Haematol. 205, 368–372 (2024).

Article  CAS  PubMed  Google Scholar 

Panaite, L. et al. Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma. Leukemia Lymphoma 63, 2918–2922 (2022).

Article  CAS  PubMed  Google Scholar 

Sesques, P. et al. Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center. Am. J. Hematol. 95, 1324–1333 (2020).

Article  CAS  PubMed  Google Scholar 

Iovino, L. et al. Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: a real-world study. J. Cell Mol. Med. 26, 5976–5983 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vercellino, L. et al. Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 4, 5607–5615 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kittai, A. S. et al. Comorbidities predict inferior survival in patients receiving chimeric antigen receptor T cell therapy for diffuse large B cell lymphoma: a multicenter analysis. Transpl. Cell Ther. 27, 46–52 (2021).

Article  CAS  Google Scholar 

Forero-Forero, J. V. et al. Predictors and management of relapse to axicabtagene ciloleucel in patients with aggressive B-cell lymphoma. Hematol. Oncol. Stem Cell. Ther. 16, 133–143 (2023).

Article  PubMed  Google Scholar 

Ghafouri, S. et al. Real-world experience of axicabtagene ciloleucel and tisagenlecleucel for relapsed or refractory aggressive B-cell lymphomas: a single-institution experience. Clin. Lymphoma Myeloma Leuk. 21, 861–872 (2021).

Article  CAS  PubMed  Google Scholar 

Bachy, E. et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat. Med. 28, 2145–2154 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Neelapu, S. S. et al. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 135, 2106–2109 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fitzgerald, L. et al. Real-world outcomes of elderly patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR-T) therapy [abstract]. J. Clin. Oncol. 38 (Suppl. 15), 8039 (2020).

Article  Google Scholar 

Bethge, W. A. et al. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood 140, 349–358 (2022).

CAS  PubMed  Google Scholar 

Zettler, M. E. et al. Real-world analysis of adverse events associated with CAR T-cell therapy among adults age ≥65 years [abstract]. Blood 134 (Suppl. 1), 1951 (2019).

Article  Google Scholar 

Gajra, A. et al. Neurological adverse events following CAR-T cell therapy: a real-world analysis of adult patients treated with axicabtagene ciloleucel or tisagenlecleucel [abstract]. Blood 134 (Suppl. 1), 1952 (2019).

Article  Google Scholar 

Nagle, S. J. et al. Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies. Am. J. Hematol. 96, 455–461 (2021).